BACKGROUND The relevance of prostate-specific membrane antigen (PSMA) targeting in the clinical management of prostate cancer (PCa) is continually increasing, entailing the development of PSMA-targeted molecular probes. Recently, a first PSMA-targeted theranostic concept has been successfully implemented by [(68)Ga/(177)Lu]PSMA-I&T. To further exploit the excellent PSMA-targeting characteristic...

BACKGROUND Due to its high expression in prostate cancer, PSMA (prostate-specific membrane antigen) represents an ideal target for both diagnostic imaging and endoradiotherapeutic approaches. Based on a previously published highly specific PSMA ligand ([(68)Ga]DOTA-FFK(Sub-KuE)), we developed a corresponding metabolically stable 1,4,7,10-tetraazacyclododececane,1-(glutaric acid)-4,7,10-triaceti...

Recently, positron emission tomography (PET) imaging using PSMA-ligands has gained high attention as a promising new radiotracer in patients with prostate cancer (PC). Several studies promise accurate staging of primary prostate cancer and restaging after biochemical recurrence with (68)Ga-PSMA ligand Positron emission tomography/computed tomography (PET/CT). However, prospective trials and cli...

UNLABELLED The expression of prostate-specific membrane antigen (PSMA) is increased in prostate cancer. Recently, (68)Ga-PSMA (Glu-NH-CO-NH-Lys-(Ahx)-[(68)Ga(HBED-CC)]) was developed as a PSMA ligand. The aim of this study was to investigate the detection rate of (68)Ga-PSMA PET/CT in patients with biochemical recurrence after radical prostatectomy. METHODS Two hundred forty-eight of 393 pati...

PURPOSE We performed a voxel-wise comparison of (68)Ga-HBED-CC-PSMA PET/CT with prostate histopathology to evaluate the performance of (68)Ga-HBED-CC-PSMA for the detection and delineation of primary prostate cancer (PCa). METHODOLOGY Nine patients with histopathological proven primary PCa underwent (68)Ga-HBED-CC-PSMA PET/CT followed by radical prostatectomy. Resected prostates were scanned ...

UNLABELLED The objective of this study was to analyze the safety and efficacy of the (177)Lu-labeled DOTAGA-based prostate-specific membrane antigen (PSMA) ligand (177)Lu-DOTAGA-(I-y)fk(Sub-KuE) ((177)Lu-PSMA) in patients with metastatic castration-resistant prostate cancer (mCRPC). METHODS Fifty-six mCRPC patients underwent PSMA radioligand therapy (RLT) with (177)Lu-PSMA. (68)Ga-PSMA-(N,N'-...

Introduction: Prostate-specific membrane antigen (PSMA) has been demonstrated as a promising tool for specific imaging of prostate cancer (PCa) via positron emission tomography-computed tomography (PET/CT) scanning. Radiation treatment planning (RTP) based on 68Ga-PSMA PET/CT scanning can also lead to some decision modifications.  The specific goal o...

Abstract Background Recent studies reported metabolic uptake in at least one of the evaluated ganglia 98.5% patients undergoing 68 Ga -PSMA-11 and 96.9% 18 F-DCFPyL PET/CT examination. We have observed different patterns ganglion visualization with compared to Ga-PSMA-11. This includes more frequent cervical sacral ganglia, which may be attributable better imaging characteristics F PET imaging....

Abstract Background The stability of precursors and reagents is utmost importance for developing a robust radiolabelling method that provides high constant radiochemical yield purity. While performing the QC [ 68 Ga]Ga-PSMA-11 injectable solutions according to Ph. Eur. Monograph has recently been published, trend instability standard PSMA-11, same used as precursor radiosynthesis, observed. Thi...